Evidence map›Paper›PMID 28894401›Full record

ArticleThe Malaysian journal of medical sciences : MJMS2017

Soluble Fas Ligand as a Potential Marker of Severity of Dengue Infection.

Nurfadly Zain, Suhartono Taat Putra, Umar Zein, Herman Hariman

Open access · diamondAbstract read
In one paragraph

Article in The Malaysian journal of medical sciences : MJMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Host immune response against DENV and ZIKV infections.Frontiers in cellular and infection microbiology · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Nurfadly ZainDepartment of Tropical Medicine, Faculty of Medicine, Muhammadiyah University of North Sumatera, Medan, Indonesia.
Suhartono Taat PutraDepartment of Pathobiology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Umar ZeinDepartment of Internal Medicine, Faculty of Medicine, Islamic University of North Sumatera Medan, Medan, Indonesia.
Herman HarimanDepartment of Clinical Pathology, Faculty of Medicine, University of North Sumatera, Medan, Indonesia.
Airlangga University · IDUniversitas Muhammadiyah Sumatera Utara · IDUniversitas Sumatera Utara · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe apoptosis of microvascular endothelial cells causes plasma leakage in dengue haemorrhagic fever patients. The soluble Fas ligand is a protein with molecular weight of 40 kDa that acts as a mediator of apoptosis. This study aimed to prove whether soluble Fas ligand can be used as a potential marker to predict the severity of dengue infection by comparing the soluble Fas ligand levels in dengue fever (DF) and dengue haemorrhagic fever (DHF) patients early in the course of illness.

methodThis was a prospective study. It included 42 dengue patients (22 DF patients and 20 DHF patients) and 20 healthy people as a control group. The soluble Fas ligand was measured by the enzyme-linked immunosorbent assay (ELISA).

resultSoluble Fas ligand was increased significantly (

conclusionSoluble Fas ligand can be used as a potential marker to predict the severity of dengue infection in the early course of the illness. However, a larger sample size and further objective studies are needed to confirm these findings.

Indexed as

dengue feverdengue hemorrhagic feverFas ligand

Identifiers

PMID28894401
PMCPMC5566059
OpenAlexW2609075708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.